Literature DB >> 19266489

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.

Nicola Winstone1, Ana Guimarães-Walker, Joanna Roberts, Denise Brown, Vanessa Loach, Nilu Goonetilleke, Tomás Hanke, Andrew J McMichael.   

Abstract

Induction of a long-term immunological memory, which can expand and defend the host upon pathogen encounter, is the "holy grail" of vaccinology. Here, using a sensitive cultured IFN-gamma ELISPOT assay, we show that 50% (15 out of 30) of healthy, HIV-1/2-uninfected volunteers who received pTHr.HIVA DNA prime-modified vaccinia virus Ankara. HIVA boost vaccine regimen 1 to 3 1/2 years ago had detectable HIV-1-specific T-cell responses. These T cells, predominantly of the CD4(+) subtype, could proliferate and produce multiple cytokines in response to in vitro peptide stimulation. Peptide mapping studies showed that the vaccine-induced CD4(+) T cells were mostly directed toward epitopes targeted in HIV-1-infected individuals. In addition, we used the same assay to re-evaluate 51 volunteers from past vaccine trial IAVI-006 and corrected the previously reported 10% of vaccine responders to 50%. Thus, we confirmed that cultured assays are a valuable tool for studying T-cell memory. These results are discussed in the context of the current state-of-affairs of the HIV-1 vaccine field.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19266489     DOI: 10.1002/eji.200839167

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Characterization of T-cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 vaccine.

Authors:  Anne Bet; Sarah Sterrett; Alicia Sato; Anju Bansal; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

2.  Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Authors:  Maximillian Rosario; Richard Hopkins; John Fulkerson; Nicola Borthwick; Máire F Quigley; Joan Joseph; Daniel C Douek; Hui Yee Greenaway; Vanessa Venturi; Emma Gostick; David A Price; Gerald W Both; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

3.  Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush-derived T cells from the female genital tract of HIV-infected women.

Authors:  Alfred Bere; Lynette Denny; Willem Hanekom; Wendy A Burgers; Jo-Ann S Passmore
Journal:  J Immunol Methods       Date:  2010-02-08       Impact factor: 2.303

4.  Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10.

Authors:  Akram A Da'dara; Donald A Harn
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

5.  Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.

Authors:  Eric Tran; Julie S Nielsen; Darin A Wick; Alvin V Ng; Lisa D S Johnson; Nancy J Nesslinger; Elissa McMurtrie; John R Webb; Brad H Nelson
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

Review 6.  Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays.

Authors:  Sandra A Calarota; Fausto Baldanti
Journal:  Clin Dev Immunol       Date:  2013-11-11

7.  A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.

Authors:  Muhammed O Afolabi; Jorjoh Ndure; Abdoulie Drammeh; Fatoumatta Darboe; Shams-Rony Mehedi; Sarah L Rowland-Jones; Nicola Borthwick; Antony Black; Gwen Ambler; Grace C John-Stewart; Marie Reilly; Tomáš Hanke; Katie L Flanagan
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

8.  Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.

Authors:  José R Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Jonatan Ersching; Cibele A Tararam; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

9.  A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Authors:  Anne Fournillier; Lars Frelin; Emilie Jacquier; Gustaf Ahlén; Anette Brass; Estelle Gerossier; Fredrik Holmström; Kate E Broderick; Niranjan Y Sardesai; Jean-Yves Bonnefoy; Geneviève Inchauspé; Matti Sällberg
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

10.  CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.

Authors:  Rebecca J Platt; Tansi Khodai; Tim J Townend; Helen H Bright; Paul Cockle; Luis Perez-Tosar; Rob Webster; Brian Champion; Timothy P Hickling; Fareed Mirza
Journal:  Cells       Date:  2013-01-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.